Entero Therapeutics, Inc. Announces Reverse Stock Split

Core Viewpoint - Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split to comply with Nasdaq listing requirements, aiming to enhance shareholder value and maintain its market presence [1][2][4]. Company Actions - The reverse stock split was approved by the Board of Directors and shareholders, and it will take effect on August 18, 2025, with trading on a split-adjusted basis [2][1]. - The reverse split will consolidate approximately 4.77 million shares into about 1.59 million shares, eliminating fractional shares by providing cash compensation instead [3][1]. Management Commentary - Richard Paolone, Interim CEO, emphasized the necessity of the reverse split for maintaining Nasdaq listing, which is crucial for increasing visibility and credibility, thereby enhancing shareholder value [4]. Company Overview - Entero Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing targeted, non-systemic therapies for gastrointestinal diseases, including Adrulipase for patients with exocrine pancreatic insufficiency [4].